

Amendments to the Claims

The listing of claims below is intended to replace all prior listings of claims presented in the above-identified application.

1-6. (canceled)

7. (currently amended) A method for inducing angiogenesis in a patient that has cardiac ischemia, said method comprising:

administering a trk receptor ligand to the patient in an amount effective to induce angiogenesis and to treat the cardiac ischemia, wherein said trk receptor ligand is selected from the group consisting of brain derived neurotrophic factor, NT-3, and NT-4.

8. (canceled)

9. (currently amended) A method for inducing angiogenesis in a patient that has a vascular disorder, said method comprising:

administering a trk receptor ligand to the patient in an amount effective to induce angiogenesis and to treat the vascular disorder, wherein said trk receptor ligand is selected from the group consisting of brain derived neurotrophic factor, NT-3, and NT-4.

10. (previously presented) A method according to claim 55, wherein said non-cardiac vascular disorder is selected from the group consisting of atherosclerosis and renal vascular disease.

11-17. (canceled)

18. (original) A method according to claim 7, wherein said administering comprises:

delivering a nucleic acid sequence encoding said trk receptor ligand.

19. (previously presented) A method according to claim 7, wherein said administering is carried out orally, intravenously, intramuscularly, intraperitoneally, subcutaneously, by intranasal instillation, by application to mucous membranes, or by instillation into hollow organ walls or newly vascularized blood vessels.

20-54 (canceled)

55. (previously presented) A method according to claim 9, wherein said vascular disorder is a non-cardiac vascular disorder.

56-58. (canceled).

59. (previously presented) A method according to claim 9, wherein said administering comprises:

delivering a nucleic acid sequence encoding said trk receptor ligand.

60. (previously presented) A method according to claim 9, wherein said administering is carried out orally, intravenously, intramuscularly, intraperitoneally, subcutaneously, by intranasal instillation, by application to mucous membranes, or by instillation into hollow organ walls or newly vascularized blood vessels.